Cancer Immunology Community Seeks Better End Points
November 29, 2016
Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
Continue reading here.
It took nearly 50 years to work out the identity of a caribou-like fossil first discovered by construction workers.
Language model delivers predictions that rival years of lab work.